Recombinant Human Anti-Alpha-GalCer Soluble TCR (C-Cys) (VS-0622-YF2729) (CAT#: VS-0622-YF2729)
Human TCR recognizes Alpha-GalCer peptide in the context of CD1d. Soluble TCR is expressed with C-terminal Cys strategy (TRAV-TRAC partial-Cys, TRBV-TRBC partial-Cys). Depending the C-terminal Cys, two chains form heterodimer. Please note that the activity is not guaranteed.
Specific Inquiry
Specifications
- Host Species
- Human
- Target
- Alpha-GalCer
- MHC
- CD1d
- Type
- Soluble TCR (C-Cys)
- Related Disease
- Cancer and autoimmune diseases
- TCR Expression Strategy
- C-Cys strategy: the alpha and beta chain (without transmembrane and cytosolic region) can form heterodimer based on C-terminal Cys. The soluble TCR contains variable regions and partial constant regions.
Target
- Alternative Names
- α-GalCer; Alpha-Galactosylceramide
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-0622-YF2729. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: WB, IF, IP, Neut, FuncS, ELISA, FC
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, WB
Application: WB, ELISA, IF
Application: ELISA, IHC, FC, IP, IF, FuncS
Application: ELISA, IHC, FC, IP, IF, Inhib
Application: ELISA, Neut
Application: ELISA, FuncS, Neut, IF, WB, EM, Inhib, IHC
Application: ELISA, FC, WB, Inhib, IHC
Application: IB, FC, ELISA, FuncS
Application: ELISA, Neut
For Research Use Only. Not For Clinical Use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.